Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07842146

The Effect of Urolithin A (Mitopure®) on Alzheimer's Disease

Sponsor: University Hospital, Akershus

View on ClinicalTrials.gov

Summary

The overall aim of MITO-AD is to evaluate if the nutritional supplement urolithin A is associated with favourable changes in Alzheimer's disease-related biomarkers, cognitive measures, and safety/tolerability outcomes in symptomatic patients with early-stage, biomarker-defined Alzheimer's disease. To do this, we will use two groups: one will be given standard care plus the food supplement urolithin A (the test group), and the other will be given just standard care plus a placebo (the control group). To measure potential differences between the groups, we will: * Do clinical and neuropsychological assessments at baseline and follow-up visits, with main biomarker sampling at baseline, week 24, and week 48. (Additional safety, tolerability, compliance, and questionnaire-based assessments will be performed during the study.) * Test blood samples from these patient groups for differences in various biomarkers to assess biological differences between them, and * Test cerebrospinal fluid (CSF) from a voluntary sub-cohort who will undergo CSF sampling at baseline and Week 4 to assess urolithin A exposure. N.B. Both groups will continue standard-of-care symptomatic Alzheimer's disease treatment as prescribed by the treating physician (where applicable). Standard of care may include acetylcholinesterase inhibitors and/or memantine. Participants receiving standard symptomatic Alzheimer's disease treatment must have been on a stable dose for at least 8 weeks prior to screening. Participants receiving anti-amyloid disease-modifying therapy will not be enrolled

Official title: A Phase II Clinical Trial on the Effect of a Mitophagy Inducer Urolithin A on Alzheimer's Disease

Key Details

Gender

All

Age Range

55 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-09-26

Completion Date

2028-10-15

Last Updated

2026-10-08

Healthy Volunteers

Conditions

Alzheimer's Disease (AD)Early Alzheimer's Disease Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions

DIETARY_SUPPLEMENT

Urolithin A

Softgels providing 1000 mg of Mitopure®/urolithin A, taken orally once daily from day 1 and continuing for 48 weeks.

DIETARY_SUPPLEMENT

Placebo Control

Matching placebo softgels, taken once daily from day 1 and continuing for 48 weeks.

Inclusion Criteria: IN-1. Participants must be between 55 and 85 years of age at the time of inclusion. IN-2. Participants must meet the National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria for Alzheimer's disease (AD) IN-3. Participants must have evidence of AD pathology, confirmed by either a positive amyloid PET imaging result or cerebrospinal fluid (CSF) biomarkers reflecting amyloid pathology (e.g., decreased Aβ42 levels or decreased Aβ42/40 ratio, and increased levels of p-Tau181, and total Tau) IN-4. Participants must have a Mini-Mental State Examination (MMSE) score of ≥24. IN-5. Participants must have been on stable doses of FDA-approved AD medications (e.g., cholinesterase inhibitors) for at least 8 weeks prior to screening IN-6. Participants must possess adequate visual and auditory acuity to complete testing IN-7. Participants must speak fluent Czech. IN-8. Participants must have a reliable study partner. IN-9. Participants must have the ability to provide written consent to participate. IN-10. Participants must be capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol Exclusion Criteria: EX-1. Participants will be excluded if they do not have clinically diagnosed AD. EX-2. Participants will be excluded if they have significant neurological conditions other than AD (e.g., Parkinson's disease, frontotemporal dementia, or vascular dementia), a history of head trauma with persistent neurological deficits, or baseline neuroimaging indicating cortical stroke or severe ischemic disease EX-3. Participants will be excluded if they have suffered from psychiatric conditions such as major depressive disorder (within the past year), bipolar disorder, or schizophrenia will be excluded EX-4. Participants will be excluded if they have had recent substance use disorder (past 2 years) EX-5. Participants will be excluded if they have unstable systemic illnesses including hepatic or renal failure EX-6. Participants will be excluded if they have decompensated diabetes EX-7. Participants will be excluded if they are taking medications with anticholinergic effects EX-8. Participants will be excluded if they are taking dietary supplements containing nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) EX-9. Participants will be excluded if they have significant spinal disease complicating lumbar puncture or with anticoagulant therapy (only for the CSF group) EX-10. Participants will be excluded if they have participated in another investigational trial within the past 3 months or have medical conditions that could jeopardise their safety or affect study results, as judged by the investigator

Locations (1)

Second Faculty of Medicine, Charles University

Prague, Czechia